Home / Markets

Markets

Peptide supply requirements in 35 European markets.

Click a country for the regulator, the published position, and every source dated and linked.

35 markets 141 dated sources Reviewed 2026-08-20

Regulatory position by compound and market: what each regulator has published about each compound, with the source on every cell.

MarketCodeSourcesSummary
Britain and Ireland2
IrelandIE2 sourcesThe HPRA detained 763,027 dosage units of falsified or unauthorised medicines in 2025. Ireland is Englis...
United KingdomGB7 sourcesThe United Kingdom prohibits the sale or supply of any unauthorised medicinal product outright under the...
German-speaking markets3
AustriaAT3 sourcesBASG has published a dedicated position holding that a research-use label does not change a peptide's cl...
GermanyDE2 sourcesGermany applies the Arzneimittelgesetz alongside anti-doping legislation, and sets criminal thresholds f...
SwitzerlandCH5 sourcesSwissmedic regulates therapeutic products under the Heilmittelgesetz and runs a named, active cross-agen...
Benelux2
BelgiumBE3 sourcesBelgium applies EU medicines law through the FAGG, which has published a GLP-1 warning. No dedicated pos...
NetherlandsNL3 sourcesThe IGJ and the NVWA assess offerings jointly and have stated their position on research-use framing dir...
Nordics5
DenmarkDK5 sourcesLaegemiddelstyrelsen maintains standing warnings, including on Melanotan. Research-chemical framing is a...
FinlandFI2 sourcesFimea has warned against injectable peptides sold through social media. Semaglutide is a prescription me...
IcelandIS6 sourcesIceland applies the Medicinal Products Act No. 100/2020, administered by the Icelandic Medicines Agency....
NorwayNO8 sourcesNorway applies the legemiddelloven and criminalises trade in listed doping substances under the general ...
SwedenSE5 sourcesLakemedelsverket has a published position on Melanotan II, and a government-commissioned report quantifi...
Baltics3
EstoniaEE2 sourcesRavimiamet published a dated statement in June 2026 addressing internet-sold peptides marketed for resea...
LatviaLV4 sourcesThe ZVA regulates under the Farmacijas likums and has published dated GLP-1 safety communications. No pe...
LithuaniaLT4 sourcesThe VVKT regulates under the Farmacijos istatymas and requires a wholesale distribution licence. No posi...
Central and Eastern Europe6
CroatiaHR1 sourcesHALMED has published a general rule on online medicine sales. No notice naming research-labelled peptide...
CzechiaCZ2 sourcesSUKL holds that most synthetic peptides meet the functional definition of a medicinal product, so classi...
HungaryHU5 sourcesOGYEI regulates medicines under Act XCV of 2005. A case-by-case research permit exists for controlled su...
PolandPL2 sourcesGIF and GIS have issued a joint public warning on synthetic peptides offered as chemical reagents. The P...
SlovakiaSK3 sourcesSUKL named BPC-157, ipamorelin and melanotan directly in a July 2025 press release tied to an INTERPOL o...
SloveniaSI2 sourcesJAZMP published a dated warning on injectable peptides in April 2026 and names semaglutide and somatropi...
Southern Europe4
FranceFR3 sourcesANSM names compounds individually in its public alerts and has issued sanitary-police decisions against ...
ItalyIT1 sourcesAIFA regulates under the Codice del farmaco and has warned on illegal GLP-1 supply through unauthorised ...
PortugalPT5 sourcesINFARMED governs medicines under the Estatuto do Medicamento and has flagged a rise in illegal online su...
SpainES2 sourcesAEMPS has issued a formal notice on illegal GLP-1 supply and directs buyers to verify pharmacies through...
Eastern Mediterranean2
GreeceGR4 sourcesEOF issued a public warning in July 2026, and related reporting names specific compounds. Regulatory att...
TurkeyTR6 sourcesTurkey applies Law No. 1262 on Pharmaceutical and Medicinal Preparations of 1928 together with the regul...
Western Balkans4
AlbaniaAL7 sourcesAlbania applies Law no. 105/2014 on medicinal products and the pharmaceutical service, as amended, admin...
Bosnia and HerzegovinaBA5 sourcesBosnia and Herzegovina applies a single state-level act, the Law on Medicinal Products and Medical Devic...
North MacedoniaMK7 sourcesNorth Macedonia applies the Law on Medicines and Medical Devices, published in the official gazette in 2...
SerbiaRS5 sourcesSerbia applies the Law on Medicines and Medical Devices, published in the official gazette in 2010 and a...
Eastern Europe2
MoldovaMD6 sourcesMoldova replaced its medicines statute in 2025: Law No. 153 of 19 June 2025 was published in the officia...
UkraineUA6 sourcesUkraine regulates medicines under the Law on Medicinal Products of 4 April 1996, enforced by the State S...
South-eastern EU2
BulgariaBG5 sourcesThe BDA regulates under the national medicines law and participates in the EU counterfeit-GLP-1 warning ...
RomaniaRO3 sourcesANMDMR operates under the EU medicines framework and has publicly identified a fraudulent tirzepatide pr...
Tell us the compounds and the market you sell into.Ask about a market

How to read these

Every position is sourced and dated

Each market page names its regulator, carries a review date, and lists every source with a link to the issuing body, so any statement on it can be checked at origin.

35 markets, 141 dated sources. This is the reference we use ourselves when a buyer asks whether a compound can be supplied into their market. It is published so the answer is available before you ask for it.

Reviewed 2026-08-20, next review 2026-11-18. Not legal advice; full terms of supply are set out in our terms.

Send an enquiry

Compounds, indicative volumes, delivery country. We reply within one working day.

Anything else you already know. All optional.

We supply businesses across Europe, and we reply within one working day.